MOH
- Marketing authorisation holder: CHECKPOINT THERAPEUTICS INC
- Status: likely_approved
Unloxcyt (COSIBELIMAB) regulatory status in United Arab Emirates.
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Yes. MOH has authorised it.
CHECKPOINT THERAPEUTICS INC holds the UAE marketing authorisation.